Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
Mayo Clinic
Mayo Clinic
Bayer
Thomas Jefferson University
SWOG Cancer Research Network
University of Washington
Rutgers, The State University of New Jersey
PCI Biotech AS
Roswell Park Cancer Institute
Diffusion Pharmaceuticals Inc
Takeda
University of California, San Francisco
Stanford University
Endo Pharmaceuticals
Dendreon
Beth Israel Deaconess Medical Center
Hoffmann-La Roche
Hoffmann-La Roche